What is the difference between isolate, broad-spectrum, and full-spectrum CBD?

Isolate is pure CBD with no THC; broad-spectrum includes multiple cannabinoids without THC; full-spectrum includes the full plant profile with up to 0.3% THC.

Is your CBD THC-free?

Our isolate and broad-spectrum products are THC-free. Product pages and labels list exact cannabinoid content.

How do I take CBD oil?

Most people place the oil under the tongue for 60-90 seconds before swallowing; start low and adjust gradually.

Hemp-derived CBD is federally legal under the 2018 Farm Bill; check your local regulations.

How do I place an order?

Choose a product above and tap Order, or email info@cbdrastro.com and we'll confirm your order by email.

CBD Rastro | Premium CBD Oil & Hemp Wellness

Educational

The New Federal Hemp Definition: What Section 781 Changes for Shoppers in 2026

The rules that define legal hemp are shifting. In November 2025, the Continuing Appropriations Act, 2026 (P.L. 119-37) rewrote the federal definition of hemp, and its hemp provisions (Section 781) are scheduled to take effect on November 12, 2026. According to a Congressional Research Service analysis, the change moves away from measuring only delta-9 THC on a dry-weight basis and toward a "total THC" concept, while also capping finished consumable products at no more than 0.4 milligrams of total THC per container.

In practical terms, that is a much stricter ceiling than the prior 0.3% delta-9 dry-weight threshold from the 2018 Farm Bill, and it is designed to sweep in intoxicating cannabinoids such as delta-8 that had grown from a regulatory gap. The law carves out genuine industrial hemp grown for fiber, grain, and non-cannabinoid seed derivatives. Several bills, including proposals to strike Section 781 or replace it with a regulated framework, are still moving through Congress, so the details could change before the effective date.

What does this mean for you as a shopper? Expect labels, formulations, and available products to keep evolving over the coming year, and lean harder than ever on batch-matched third-party lab reports. None of this is legal advice, and separate from any of these debates, the FDA has consistently held that CBD is not an approved food additive or dietary ingredient. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Talk with your healthcare provider before using any cannabinoid product.

Sources: Congress.gov (CRS); Congress.gov (CRS); FDA

Jul 4, 202611 min read

Informative

How to Read a 2026 Certificate of Analysis: Total THC, Uncertainty, and ISO 17025

A certificate of analysis (COA) is the most reliable tool a shopper has, and the standards behind it are tightening. USDA laboratory testing guidelines for the domestic hemp program require labs to validate their methods and to estimate and report measurement uncertainty alongside THC results, because so much rides on the legal threshold. After December 31, 2024, labs performing official THC testing must also be registered with the DEA to handle controlled substances.

When you open a COA, check that the batch number matches your product, that it reports total cannabinoids, and that it screens for pesticides, residual solvents, and heavy metals. As the federal standard moves toward a "total THC" measure in late 2026, expect reports to foreground total THC rather than delta-9 alone. Many reputable labs hold ISO/IEC 17025 accreditation, an international benchmark for technical competence and impartiality that makes results more widely trusted.

A COA cannot promise a health outcome. The National Center for Complementary and Integrative Health notes that independent testing has repeatedly found CBD products whose actual content differs from the label, which is exactly why the paperwork matters. This is general information, not medical or legal advice. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Sources: USDA AMS; NIH NCCIH

Jul 9, 20267 min read

Field Notes

Field Notes: Why We Rewrote Our Marketing Copy This Summer

This month we did an unglamorous but important job: a top-to-bottom audit of the words we use to describe our products. The prompt was a reminder of how seriously regulators treat advertising. The FTC has continued health-marketing enforcement into 2026, and its long-standing guidance is blunt — claims that a CBD product treats or prevents a disease, or delivers drug-like benefits, need rigorous human clinical evidence behind them. If a company cannot muster that proof, it simply should not make those claims.

So we went line by line. We cut anything that implied our extracts could cure, treat, or prevent a condition, tightened our serving-size language, and made sure every product page links to its batch-matched lab report. Meanwhile, the FDA has scheduled a 2026 public meeting on the scope of dietary supplement ingredients under DSHEA, a sign that the ground rules for supplements are being actively re-examined — all the more reason to describe products honestly and modestly.

We would rather under-promise and keep your trust than borrow language the science does not support. Nothing here is medical advice. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Please consult your healthcare provider before adding any cannabinoid or supplement to your routine, especially if you take other medications.

Sources: FTC; FTC; FDA

Jul 15, 20265 min read

Devin Lockett

Devin Lockett is the founder and entrepreneur behind this venture and the wider BiomedRx family of companies—spanning healthcare technology, wellness, media, and community initiatives. He builds brands focused on quality, service, and independent ownership.